<DOC>
	<DOCNO>NCT01398501</DOCNO>
	<brief_summary>Sorfenib work slow spread cancer cell . It use study patient AML FLT3-ITD mutation information study suggest sorafenib may help control leukemia . The purpose study find high dose sorafenib maintenance therapy safely use participant AML undergone allogeneic stem cell transplant .</brief_summary>
	<brief_title>Sorafenib Maintenance Therapy Patients With AML After Allogeneic Stem Cell Transplant</brief_title>
	<detailed_description>Subjects take sorafenib orally either twice daily . Subjects come Bone Marrow Transplant Clinic 3 time ( Day 8 , 15 , 30 ) first month treatment . After first month , see every month 3 month 9 6 9 month . Subjects physical exam ask question regard general health specific question problem might medications take . Subjects standard blood test every month 12 month check liver kidney function complete blood count . Subjects research blood test Days 8 , 15 30 first month treatment . Subjects bone marrow biopsy 3 month 12 month treatment . Subjects receive treatment 12 month follow 1 year completing study .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Subjects AML FLT3ITD mutation undergone allogeneic HSCT Peripheral blood chimerism study show &gt; /= 70 % cell donor origin Adequate hematologic hepatic function ECOG performance status 02 Able swallow whole pill Evidence relapsed/recurrent/residual disease assess bone marrow aspirate biopsy perform day 3060 HSCT Active acute graft v host disease require equivalent dose &gt; 0.5 mg/kg/day prednisone equivalent patient necessitate addition another agent treatment GVHD beyond corticosteroid Ongoing uncontrolled infection Cardiac disease : congestive heart failure &gt; class II NYHA , unstable angina new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month Cardiac ventricular arrhythmia require antiarrhythmic therapy Uncontrolled hypertension Known HIV infection chronic hepatitis B C Thrombotic embolic event cerebrovascular accident include transient ischemic attack within past 6 month Pulmonary hemorrhage/bleeding event &gt; CTCAE v 4.0 Grade 2 within 4 week start study drug Any hemorrhage/bleeding event &gt; CTCAE v. 4.0 Grade 3 within 4 week start study drug Serious nonhealing wound , nonhealing ulcer , bone fracture Evidence history bleed diathesis coagulopathy Major surgery significant traumatic injury within 4 week start study drug Use St. John 's Wort rifampin ( rifampicin ) Known suspect allergy sorafenib Pregnant breastfeeding Receiving investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AML</keyword>
	<keyword>FLT3-ITD</keyword>
	<keyword>Stem cell transplant</keyword>
</DOC>